CVRx Receives Innovator of the Year Award; Company Recognized for Developing Implantable Medical Device to Treat High Blood Pressure.
"In just a few years, our exceptional team has advanced a promising concept to the point where we are now providing therapy to patients in clinical trials, and we are delighted with the results thus far," said Kieval. "We have demonstrated that Rheos can reduce blood pressure in patients, and we are working closely with the FDA on plans for a pivotal clinical trial of our product. This unique approach to managing high blood pressure has the potential to improve the lives of patients with high blood pressure and prevent more serious disease."
Approximately 25 percent of people with hypertension cannot control their high blood pressure, despite the use of multiple medications. High blood pressure, or hypertension, affects about 65 million people in the United States. It is a leading cause of stroke, heart attack, heart failure and kidney disease and causes an estimated one in every eight deaths worldwide.
About CVRx: CVRx was founded in 2001. The Rheos System is an implantable device that is designed to reduce blood pressure by using mild electrical signals to influence the body's blood pressure regulation system, known as the baroreflex. This investigational device is currently in clinical trials in Europe and the United States. For more information visit www.cvrx.com.
About Finance & Commerce: Finance and Commerce is the only daily newspaper in the Minneapolis and St. Paul area that is devoted exclusively to business. Each year Finance & Commerce recognizes pioneering companies that have demonstrated an innovative spirit and developed creative products and solutions.
CAUTION: CVRx Rheos System is an investigational device and is limited by Federal (or United States) law to investigational use only.
CVRx, Rheos, Baroreflex Hypertension Therapy are trademarks of CVRx, Inc. (C) CVRx, Inc. 2005